Global Ewing Sarcoma Drug Market
Ewing sarcoma drug are pharmaceuticals that are designed for the treatment of Ewing’s sarcoma, a rare cancerous tumor prevalent in the patient’s bones, soft tissues and nerves surrounding the bones. Due to the rareness of the disease, effective treatment methods of this disease are highly limited and therefore majority of the companies are dealing in the development of effective pharmaceuticals that can reduce the prevalence of cancer in patients.
Access Full Report at https://www.databridgemarketresearch.com/reports/global-ewing-sarcoma-drug-market
Ewing sarcoma drug market is growing due to increasing incidences of Ewing sarcoma worldwide, initiatives taken by government organizations to reduce the rate of morbidity caused by Ewing sarcoma; the effects of these factors are mentioned below:
- Increasing incidences of Ewing sarcoma worldwide: Although, this type of cancer is rare in prevalence the incidence rate of population suffering from this disease is on the rise globally as the cases of bone tumors arising in patients has had a significant impact on the prevalence of Ewing’s sarcoma. This incidence rate has given rise to the demands for various treatment modes and therapeutics for this disorder
- Initiatives taken by government organizations to reduce the rate of morbidity: Due to the increasing incidences of the disease, governments of different regions have initiated various programs and promoted the awareness amongst individuals as well as pharmaceutical manufacturers for the development of effective Ewing’s sarcoma drugs. These initiatives have been focused on the reduction of morbidity rate associated with this disease which causes a significant impact on the healthcare expenditure for a region
Approval of innovative drugs and conclusion of clinical trial for these drugs:
- In August 2019, Cellectar Biosciences, Inc. announced that they had completed the first cohort of malignant brain tumor patients for the currently undergoing Phase I trial of CLR 131 for children and adolescents. The candidate is accelerating through its study at a good pace and the company is currently exploring the next steps and dosage to gather more information regarding the effectiveness of the drug candidate
- In August 2018, Gradalis, Inc. announced that they had initiated the Phase III clinical trial for “Vigil” to treat individuals suffering from Ewing’s sarcoma. The company will look towards reaching other individual targets for this drug by utilizing the company’s immunotherapy platform for cancer treatment
The market is segmented on the basis of types as bone tumor, soft tissue (Extra-Osseous) tumor, pPNET, askin tumor; diagnosis is categorized into physical exam, blood test, PET scan, X-Rays, bone scan, MRI, CAT/CT scan, bone marrow aspiration, biopsy; treatment as chemotherapy, radiation, surgery; mechanism of action as TKIs, monoclonal antibody, checkpoint inhibitors, vaccines; drugs type as vincristine, cyclophosphamide, doxorubicin, etoposide, ifosfamide, dactinomycin; route of administration as oral, intravenous, others; end-users as hospitals, homecare, specialty clinics, others.
“According to Data Bridge Market Research, global Ewing sarcoma drug market is expected to be growing with a steady CAGR during the forecast period of 2019 to 2026”
Some of the major players operating in market are Merck & Co., Inc, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Novartis AG, Pfizer Inc, Johnson & Johnson Services, Inc, Abbott, Sanofi, Bausch Health, Eli Lilly and Company, AbbVie Inc, Takeda Pharmaceutical Company Limited, Amgen Inc, AstraZeneca, Bristol-Myers Squibb Company, Bayer AG, DAIICHI SANKYO COMPANY, LIMITED, CELGENE CORPORATION, Eisai Co., Ltd, Gradalis, Inc, Incyte Corporation among others.
Due to the increasing prevalence of Ewing’s sarcoma, coupled with pressure from the authorities for the reduction of morbidity rate associated with the disorder. Majority of the manufacturers have taken this to enhance their research & development activities for the development of an effective therapeutic system that can be approved by the appropriate authorities and subsequently commercialized.
